News and Announcements
MatLogica’s advanced analytics increased speedups for a Tier 2 European bank by 15-20x
- Published August 11, 2022 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
MatLogica is a UK-based early-stage deep-tech company with revolutionary technology in the fields of high-performance computing and automatic adjoint differentiation. Founded by a quant with 17+ hands-on experience and a mathematician, MatLogica developed a framework that uses a fundamentally different approach to working with a CPU allowing us to extract the highest level of performance from modern hardware. Our framework is a perfect fit for finance, medical research and diagnosis, space research, geophysics, weather modelling, and more.
With the launch of their product line, Matlogica has put together a case study with a Tier 2 European Bank
Client: Tier 2 European Bank
Client problem:
To compute risk, the client’s proprietary quant system employed a combination of Bump & Revalue and manual adjoint differentiation. Despite substantial expenditure, the risk system struggled to provide risk reports on time for the next trading day.
Solution and results:
Analytics powered by MatLogica opened revenue streams, reduced infrastructure costs, and improved risk management. When compared to their old manual adjoint differentiation paired with Bump & Revalue, they obtained 15-20x speedups.
Overnight portfolio risk computation was reduced from 8+ hours to 2 hours, while intraday risk calculation was reduced from 30+ minutes to a few minutes. By reducing difficult-to-maintain elements, the modelling quant team’s pace rose threefold, allowing speedier time-to-market for new features.
Company Updates
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Beyond the Drip: Elemental IV’s Infrastructure Play for a Fragile Supply Chain
In the high-stakes world of life sciences, we often hunt for the next “miracle molecule” or gene-editing breakthrough. But Storme Paes, Founder and Commercial Director of Elemental IV, found her mission in something far more fundamental, yet dangerously overlooked: a simple bag of saltwater. The “Meeting Room” Revelation The genesis of Elemental IV didn’t occur […]
Backed By Leading Investment Groups and Family Offices
